# Xtant Medical Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2014

- Company: [Xtant Medical Holdings, Inc.](/companies/xtnt.md) (CIK 1453593)
- Form: 10-Q
- Filed: 2014-08-14
- Accepted by EDGAR: Aug 14, 2014, 13:13 ET
- Period: 2014-06-30
- Accession: 0001104659-14-060948
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1453593/000110465914060948/a14-19073_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1453593/000110465914060948/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2014-04-01 to 2014-06-30 | $8.9m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2014-01-01 to 2014-06-30 | $17.8m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2014-04-01 to 2014-06-30 | $3.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2014-01-01 to 2014-06-30 | $6.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2014-04-01 to 2014-06-30 | $5.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2014-01-01 to 2014-06-30 | $11.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2014-04-01 to 2014-06-30 | $322.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2014-01-01 to 2014-06-30 | $576.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2014-04-01 to 2014-06-30 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-01-01 to 2014-06-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2014-04-01 to 2014-06-30 | $1.4m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2014-01-01 to 2014-06-30 | $2.7m | us-gaap:InterestExpense |
| Net income | 3 months, 2014-04-01 to 2014-06-30 | −$1.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-01-01 to 2014-06-30 | −$6.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2014-01-01 to 2014-06-30 | −$1.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-04-01 to 2014-06-30 | −$0.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2014-01-01 to 2014-06-30 | −$1.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-04-01 to 2014-06-30 | 5,514,694 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2014-01-01 to 2014-06-30 | 5,447,204 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months, 2014-01-01 to 2014-06-30 | $115.2k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2014-06-30 | $3.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-06-30 | $19.4m | us-gaap:AssetsCurrent |
| Total assets | at 2014-06-30 | $28.4m | us-gaap:Assets |
| Current liabilities | at 2014-06-30 | $9.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-06-30 | $36.4m | us-gaap:Liabilities |
| Long-term debt | at 2014-06-30 | $20.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2014-06-30 | $49.2k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-06-30 | −$8.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1453593/000110465914060948/a14-19073_110q.htm

Filed Aug 14, 2014.
Source: SEC EDGAR, the filing index for accession 0001104659-14-060948. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.
